Format

Send to

Choose Destination
Drug Discov Today. 2007 Apr;12(7-8):289-94. Epub 2007 Feb 20.

Driving earlier clinical attrition: if you want to find the needle, burn down the haystack. Considerations for biomarker development.

Author information

1
Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey, GU20 6PH, UK. peck_richard_w@lilly.com

Abstract

Drug development attrition rates are rising and late phase attrition remains high, contributing to an unsustainable increase in R&D spending. Consequently, there is much effort to identify the potentially successful molecules earlier in development with the use of biomarkers to predict potential efficacy and safety. However, focussing only on picking the winners earlier will not solve the problem. It is essential that the evaluation of these biomarkers also enables the earlier termination of the molecules that will not have the required activity.

PMID:
17395088
DOI:
10.1016/j.drudis.2007.02.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center